BERGEN, Norway--(BUSINESS WIRE)--BerGenBio, an emerging oncology biopharma, today announced the appointment of Dr Sue Foden to its Board of Directors. Foden was one of the founders of Cancer Research UK and also served as CEO of both Cancer Research Campaign Technology Ltd and Cancer Research Ventures Ltd. She was also an investment director at Merlin Biosciences, advisor on several EU projects and currently holds a range of directorships including Source Bioscience plc, Elara GmbH and Vectura plc. Following a recent successful fundraising led by Sarsia Seed, Foden’s appointment represents a further strengthening of the company as it gears up to taking its lead programme BGB324, a first in class AXL inhibitor, into Phase I trials in 2012.
